Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2019 December;71(6) > Minerva Ginecologica 2019 December;71(6):434-41



Publishing options
To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Ginecologica 2019 December;71(6):434-41

DOI: 10.23736/S0026-4784.19.04466-6


language: English

Prevention of vaginal dryness in perimenopausal women. Supplementation with Lady Prelox®

Maria R. CESARONE 1, 2, Gianni BELCARO 1, 2 , Claudia SCIPIONE 1, 2, Valeria SCIPIONE 1, 2, Mark DUGALL 1, 2, Shu HU 3, Roberto COTELLESE 3, Beatrice FERAGALLI 1, 2, Andrea LEDDA 1, 2

1 IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy; 2 IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy; 3 Department of Medical, Oral Sciences and Biotechnologies, G. D’Annunzio University, Pescara, Italy

BACKGROUND: The aim of this pilot registry study was to use a standardized supplement (Lady Prelox®, Horphag Research) - including Pycnogenol®, l-arginine, L-citrulline and rose hip extract - to improve signs and symptoms associated with vaginal dryness in pre and post-menopausal healthy women. A group of women used only a standard management (SM) and a second group added Lady Prelox®.
METHODS: Four groups of women were included in the study. 34 pre-menopausal and 38 post-menopausal women took Lady Prelox®, four tablets daily for 8 weeks and 33 pre-menopausal women and 35 post-menopausal women served as controls.
RESULTS: No safety problems were observed with the supplement that was well tolerated. The subgroups of controls and supplemented subjects were comparable in both the pre- and post-menopausal groups. Among pre-menopausal women, results of the female sexual function index (FSFI) were significantly improved with the supplement in comparison with the control subjects’ group (P<0.05). The results of the FSFI questionnaire for post-menopausal women indicated a significant improvement at 8 weeks with Lady Prelox® (P<0.05) in comparison with controls. Preclinical items (vaginal dryness, pain/discomfort during intercourse, mucus, minimal infections, presence of candida and oxidative stress) were significantly improved (P<0.05) with Lady Prelox®) in comparison to minimal changes with the SM group. These measurements included all women.
CONCLUSIONS: The effects of the supplementation with Lady Prelox® on vaginal dryness were significant. The supplement was well accepted and revealed no side effects or tolerability problems. Further studies are evaluating the effects of Lady Prelox® on other aspects of the menopausal transition that may alter the quality of life of most women in advanced age. A gentle approach with suitable dietary supplementation, represents a promising option for addressing common challenges that women experience in such conditions.

KEY WORDS: Surveys and questionnaires; Dietary supplements; Coitus; Menopause; Pycnogenols; Sexual health

top of page